Table 1 Basic characteristics and antibody patterns of the study population
Variable | Total subjects (n = 22769) | Ure antibody-positive subjects (%) | P value | CagA antibody-positive subjects (%) | P value | VacA antibody-positive subjects (%) | P value | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Gender | Â | Â | Â | Â | 0.007 | Â | Â | 0.000 | Â | Â | 0.000 |
Male | 1,1594 | 4,925 | 42.48% | Â | 2,959 | 25.52% | Â | 2,508 | 21.63% | Â | |
Female | 1,1175 | 4,945 | 44.25% | Â | 3,273 | 29.29% | Â | 2,856 | 25.56% | Â | |
Age group (years) | Â | Â | Â | Â | 0.000 | Â | Â | 0.000 | Â | Â | 0.000 |
0–20 | 1,390 | 339 | 24.39% |  | 186 | 13.38% |  | 162 | 11.65% |  | |
20–30 | 1,258 | 469 | 37.28% |  | 285 | 22.66% |  | 252 | 20.03% |  | |
30–40 | 2,666 | 1,150 | 43.14% |  | 719 | 26.97% |  | 619 | 23.22% |  | |
40–50 | 3.767 | 1,734 | 46.03% |  | 1,073 | 28.48% |  | 928 | 24.63% |  | |
50–60 | 6,829 | 3,155 | 46.20% |  | 2,049 | 30.00% |  | 1,767 | 25.87% |  | |
60–75 | 6,859 | 3,023 | 44.07% |  | 1,920 | 27.99% |  | 1,636 | 23.85% |  | |